Amylyx’s Relyvrio/Albrioza Launch Chugs Along As Firm Gives EU Another Go

Amylyx announced its Q2 earnings, including an update on the launch of its ALS drug Relyvrio/Albrioza • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business